{Reference Type}: Journal Article
{Title}: CD151 and prostate cancer progression: A review of current literature.
{Author}: Kang Z;Luo Y;Xiao E;Li Q;Wang L;
{Journal}: Asia Pac J Clin Oncol
{Volume}: 19
{Issue}: 4
{Year}: Aug 2023 30
{Factor}: 1.926
{DOI}: 10.1111/ajco.13890
{Abstract}: Prostate cancer morbidity and mortality are increasing globally and in China, and the rate of metastasis is also rising, limiting the therapeutic effect and clinical prognosis of prostate cancer. CD151 is considered to be the first promoter of tumor metastasis in the tetraspanin superfamily. Previous research has linked CD151 to the progression of a number of malignancies, including prostate cancer. However, a recent study found that CD151 can inhibit the progression of prostate cancer. As a result, this paper examines existing research on CD151 and prostate cancer progression in order to clarify the relationship and provide a possible reference for future studies.